The Absurd COVID-19 Vaccine Regulatory Race
Executive Summary
Donald Trump is no longer the only one who thinks the US FDA is moving too slow on allowing broad access to COVID-19 vaccine candidates. But before the narrative that FDA’s caution cost lives takes root, let’s remember the facts: the key milestone isn’t when an effective vaccine is authorized, but when supplies are sufficient to mount an effective vaccination campaign.
You may also be interested in...
Possibility Of COVID Vaccine Production Glitches Drives Early US Dose Distribution Plan
Initial allocation plans for the Pfizer/BioNTech vaccine may change after a month or so if manufacturing scaleup proceeds ‘perfectly,’ Operation Warp Speed’s Slaoui suggests.
Flexibility And Agility Key To Speedy UK COVID Vaccine Approval
The flexibility and agility of parallel teams of scientists and clinicians who worked around the clock were key to speedy UK approval of the COVID-19 vaccine, according to UK agency head June Raine. Canada has also just announced that it has approved the Pfizer/BioNTech vaccine.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.